Skip to main content
. 2015 May 12;24(6):1019–1030. doi: 10.1002/pro.2682

Figure 4.

Figure 4

Cardiolipin reactivity of VRC07 variants. Shown is the cardiolipin ELISA results at different antibody concentrations for (A) VRC07-av1 and its glycan mutants (B) VRC07-av2 and its glycan mutants, and (C) VRC07-av3 and its glycan mutant. Synagis (Palivizumab), an anti-RSV monoclonal antibody, was used as the negative control. 2F5, a polyreactive HIV-1 antibody, was used as the positive control. In all three cases, the glycan variants had a decrease of approximately 60% to 90% in cardiolipin reactivity at the highest antibody concentration (100 µg/ml).